-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

ASH-EHA Joint Symposium

Program: Marquee Sessions
Hematology Disease Topics & Pathways:
Clinical Practice (Health Services and Quality), Diseases, Myeloid Malignancies
Sunday, December 8, 2024: 12:30 PM-1:30 PM
Hall B (San Diego Convention Center)
Co-chairs:
Mohandas Narla, DSc, New York Blood Center and Antonio Medina Almeida, MD, PhD, Hospital da Luz Lisboa
Disclosures:
Almeida: Gilead: Consultancy, Speakers Bureau; Novartis: Speakers Bureau.
Session Overview

The ASH-EHA Joint Symposium is intended to address global issues in hematology from both the North American and European perspectives and provide insight on how international collaboration can help confront these issues. The first of these sessions was held at the ASH Annual Meeting in December 2005, and has taken place twice each year since at the European Hematology Association’s (EHA) Annual Congress in June and the ASH Annual Meeting in December. The leadership of both societies determine the recommended topics and speakers for these events each year, with the society presidents co-chairing the event. This year's topic is Myelodysplasia.  

Myelodysplasia

Myelodysplasia and Myeloproliferative syndromes are complex and heterogeneous clinical entities with varying progression rates. Significant progress is being made in our understanding of the molecular and genetic basis for these disorders. These insights are being used to develop new strategies for optimal patient-specific treatment modalities for effective and optimal clinical management of these disorders.  Dr. Amy DeZern will discuss prognostication and risk stratification strategies for patients with myelodysplastic syndromes. Dr. Matteo Della Porta will discuss the targeting of cytopenias in low-risk MDS.

Matteo Giovanni Della Porta, MD

IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy

Amy E. DeZern, MD, MHS

Johns Hopkins University, Baltimore, MD; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD

See more of: Marquee Sessions